Tests stapokibatrt in children with atopic dermatitis
Tests the drug stapokibatrt in children aged 2 to 12 with atopic dermatitis.
Plain-language title generated from the registry record
Registry title: A Study of Stapokibatrt in Children Subjects With Atopic Dermatitis
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 12 years old?
Source: NCT07106372, who can take part
Where in China
- Beijing Children's Hospital, Capital Medical UniversityBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Keymed Biosciences Co.Ltd
- Trial code
- NCT07106372
- Record updated
- 6 August 2025
- Original description
This is a multi-center, single-arm, open-label phase 3 study to evaluate the safety, efficacy, Pharmacokinetics(PK) and immunogenicity of Stapokibatrt in children with Atopic Dermatitis.Read full original descriptionShow less
A Multi-center, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Stapokibatrt in Children With Atopic Dermatitis
This is a multi-center, single-arm, open-label phase 3 study to evaluate the safety, efficacy, Pharmacokinetics(PK) and immunogenicity of Stapokibatrt in children with Atopic Dermatitis.
Inclusion: Voluntarily participate in the continuing study and sign the written Informed Consent Form(ICF); Subjects who must complete the evaluation of Week 18 of the main study; Have the ability to communicate well with the researcher and comply with the follow-up visits of the protocol.
Exclusion: Planned major surgical procedure during the patient's participation in this study; Any other circumstances in which the researcher deems not suitable to participate in this study.